Entering text into the input field will update the search result below

Cellectis SA (CLLS) CEO André Choulika on Q4 2019 Results - Earnings Call Transcript

Mar. 05, 2020 11:12 PM ETCellectis S.A. (CLLS) Stock, CMVLF Stock
SA Transcripts profile picture
SA Transcripts

Cellectis SA (NASDAQ:CLLS) Q4 2019 Earnings Conference Call March 5, 2020 7:30 AM ET

Company Participants

Simon Harnest - VP, Corporate Strategy & Finance

André Choulika - Co-Founder, Chairman & CEO

Francisco Esteva - VP, Clinical Development

Eric Dutang - CFO

Conference Call Participants

Huidong Wang - Barclays Bank

Kelsey Goodwin - Guggenheim Securities

Amanda Murphy - BTIG

James Birchenough - Wells Fargo Securities

Andrea Tan - Goldman Sachs Group

Christopher Marai - Nomura Securities

Wangzhi Li - Ladenburg Thalmann & Co.

Biren Amin - Jefferies

Raju Prasad - William Blair & Company

Hartaj Singh - Oppenheimer

Samantha Semenkow - Citigroup

Bertrand Delsuc - Biotellytics


Good morning, everyone, and welcome to the Cellectis' Fourth Quarter and Full Year 2019 Results Conference Call. [Operator Instructions].

I'd now like to introduce the first speaker, Simon Harnest, Cellectis' Vice President of Corporate Strategy and Finance. You may begin, sir.

Simon Harnest

Thank you, and welcome, everyone, to Cellectis' Fiscal Year and Fourth Quarter 2019 Corporate Update and Financial Results Conference Call. Joining me on the call today with prepared remarks are Dr. André Choulika, our Chairman and Chief Executive Officer; Eric Dutang, our Chief Financial Officer; and Dr. Francisco Esteva, Vice President, Clinical Development.

Yesterday evening, Cellectis filed its annual report and issued a press release reporting our financial results for the fourth quarter and year ended December 31, 2019. The reports and press release are available on our website at cellectis.com.

As a reminder, we will make forward-looking statements regarding financial outlook in addition to regulatory and product development plans. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found in our most recent Form 20-F on file with the SEC.

I would now like

Recommended For You


To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!

About CLLS

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on CLLS

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.